How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19.

COVID-19 Epidemiological biases Measurement error Misclassification Observational data Selection bias

Journal

European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 12 11 2020
accepted: 04 02 2021
pubmed: 27 2 2021
medline: 7 4 2021
entrez: 26 2 2021
Statut: ppublish

Résumé

In response to the coronavirus disease (COVID-19) pandemic, public health scientists have produced a large and rapidly expanding body of literature that aims to answer critical questions, such as the proportion of the population in a geographic area that has been infected; the transmissibility of the virus and factors associated with high infectiousness or susceptibility to infection; which groups are the most at risk of infection, morbidity and mortality; and the degree to which antibodies confer protection to re-infection. Observational studies are subject to a number of different biases, including confounding, selection bias, and measurement error, that may threaten their validity or influence the interpretation of their results. To assist in the critical evaluation of a vast body of literature and contribute to future study design, we outline and propose solutions to biases that can occur across different categories of observational studies of COVID-19. We consider potential biases that could occur in five categories of studies: (1) cross-sectional seroprevalence, (2) longitudinal seroprotection, (3) risk factor studies to inform interventions, (4) studies to estimate the secondary attack rate, and (5) studies that use secondary attack rates to make inferences about infectiousness and susceptibility.

Identifiants

pubmed: 33634345
doi: 10.1007/s10654-021-00727-7
pii: 10.1007/s10654-021-00727-7
pmc: PMC7906244
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-196

Subventions

Organisme : NIAID NIH HHS
ID : T32 AI007535
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : T32AI007535
Organisme : NCI NIH HHS
ID : U01 CA261277
Pays : United States
Organisme : National Institute of General Medical Sciences (US)
ID : U54GM088558

Références

One Health. 2020 Dec;10:100166
pubmed: 32904481
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Nature. 2020 Dec;588(7839):553
pubmed: 33328621
Epidemiol Infect. 1990 Oct;105(2):435-46
pubmed: 2170159
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
Lancet Infect Dis. 2021 Apr;21(4):e73
pubmed: 32791041
Clin Infect Dis. 2020 Sep 23;:
pubmed: 32964919
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
J Med Virol. 2020 Nov;92(11):2804-2812
pubmed: 32542750
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
Public Health. 2020 Jun;183:110-111
pubmed: 32502699
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033172
Arch Dis Child. 2020 Aug 7;:
pubmed: 32769089
Arch Dis Child. 2020 Nov 10;:
pubmed: 33172887
Health Educ Behav. 2020 Aug;47(4):509-513
pubmed: 32436405
Clin Infect Dis. 2020 Nov 19;71(16):2099-2108
pubmed: 32392331
Clin Infect Dis. 2020 Oct 29;:
pubmed: 33119065
Int J Epidemiol. 2021 Feb 22;:
pubmed: 33615345
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Elife. 2020 Aug 21;9:
pubmed: 32820721
Eur Respir J. 2020 May 27;55(5):
pubmed: 32312864
Clin Infect Dis. 2020 Nov 5;71(8):1943-1946
pubmed: 32301964
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Dec 10;41(12):2024-2028
pubmed: 32340093
Clin Infect Dis. 2021 Jan 27;72(2):301-308
pubmed: 33501951
J Clin Microbiol. 2020 Oct 21;58(11):
pubmed: 32826322
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
Biometrics. 1981 Jun;37(2):251-8
pubmed: 7272413
Lancet. 1952 Sep 20;2(6734):549-54
pubmed: 12981903
Lancet. 2020 Mar 14;395(10227):e47
pubmed: 32113505
Epidemiology. 2010 May;21(3):383-8
pubmed: 20335814
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Nat Commun. 2021 Mar 9;12(1):1533
pubmed: 33750783
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Pediatrics. 2020 Jun;145(6):
pubmed: 32179659
J Infect Dis. 2021 Feb 13;223(3):362-369
pubmed: 33119738
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
BMJ. 2016 Dec 9;355:i6536
pubmed: 27940434
Int J Equity Health. 2020 Jun 26;19(1):104
pubmed: 32586388
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Emerg Infect Dis. 2020 Jun;26(6):1341-1343
pubmed: 32191173
Am J Epidemiol. 2021 Feb 1;190(2):328-335
pubmed: 32870977
Scientometrics. 2020 Aug 28;:1-12
pubmed: 32904414
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347198
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
Emerg Infect Dis. 2020 Oct;26(10):2465-2468
pubmed: 32673193
Clin Infect Dis. 2021 Feb 16;72(4):604-610
pubmed: 32726405
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
PLoS Pathog. 2012;8(12):e1003061
pubmed: 23271967
Emerg Infect Dis. 2020 Aug;26(8):1917-1920
pubmed: 32412896
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
Clin Microbiol Infect. 2021 Apr;27(4):511-519
pubmed: 33484843
Clin Infect Dis. 2021 Jan 06;:
pubmed: 33400782
N Engl J Med. 2020 May 28;382(22):2163-2164
pubmed: 32283004
J Infect Dis. 2020 Nov 9;222(11):1772-1775
pubmed: 32856712
Am J Epidemiol. 1977 May;105(5):488-95
pubmed: 871121
Am J Epidemiol. 2012 Jun 15;175(12):1303-10
pubmed: 22569106
BMC Bioinformatics. 2018 Oct 22;19(Suppl 11):363
pubmed: 30343663
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
J Med Virol. 1984;13(2):179-92
pubmed: 6319590
Lancet. 2020 Nov 14;396(10262):1595-1606
pubmed: 33065034
Travel Med Infect Dis. 2020 Jul - Aug;36:101803
pubmed: 32592903
Am J Epidemiol. 2009 Oct 15;170(8):959-62; discussion 963-4
pubmed: 19755635
Am J Epidemiol. 2017 Nov 15;186(10):1209-1216
pubmed: 29149252
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613

Auteurs

Emma K Accorsi (EK)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA. eaccorsi@g.harvard.edu.

Xueting Qiu (X)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Eva Rumpler (E)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Lee Kennedy-Shaffer (L)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
Department of Mathematics and Statistics, Vassar College, Poughkeepsie, NY, 12604, USA.

Rebecca Kahn (R)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Keya Joshi (K)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Edward Goldstein (E)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Mats J Stensrud (MJ)

Department of Mathematics, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

Rene Niehus (R)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Muge Cevik (M)

Division of Infection and Global Health Research, School of Medicine, University of St Andrews, St Andrews, UK.
Specialist Virology Laboratory, Royal Infirmary of Edinburgh, Edinburgh, UK.
Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.

Marc Lipsitch (M)

Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH